Jenny Q. Nguyen

Jenny Q. Nguyen

Auto-generated profile, based on publicly available information

Jenny Q. Nguyen

Personalized Care Program Children's Hospital Los Angeles Los Angeles California USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MMMaud Maillard
Maud Maillard
JNJenny Q. Nguyen
Jenny Q. Nguyen
WYWenjian Yang
Wenjian Yang
KHKeito Hoshitsuki
Keito Hoshitsuki
MRMary V. Relling
Mary V. Relling
JYJun Yang
Jun Yang

8 August 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
JNJenny Q. Nguyen
Jenny Q. Nguyen
CPCourtney Paetznick
Courtney Paetznick
RDRoseann S. Donnelly
Roseann S. Donnelly

14 October 2026 in JPGN Reports
Verified
Journal Article
Open access
PDF file
JNJenny Q. Nguyen
Jenny Q. Nguyen
NRNatalie Rodriguez
Natalie Rodriguez
KCKimberly A. Chapman
Kimberly A. Chapman
MDMatthew A. Deardorff
Matthew A. Deardorff
KHKeith Z. Hazleton
Keith Z. Hazleton
Thiopurines, such as azathioprine (AZA), are among the immunosuppressants used to prevent allograft rejection. Thiopurines are metabolized by thiopurine S‐methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) enzymes, and their functions are highly influenced by genetic variation. We present a 6‐year‐old female with recurrent acute cellular rejection and steroid‐induced glaucoma due to high‐dose corticosteroid therapy. Consequently, AZA was incorporated into her calcineurin‐inhibitor‐based regimen to reduce steroid dose. Within 33 days of initiating AZA, alopecia and pancytopenia developed despite confirmed TPMT enzyme activity with normal phenotype and low 6‐Thioguanine and 6‐Methylmercaptopurine levels in the blood. Pharmacogenomic analysis revealed an NUDT15 *3/*3 genotype, indicating two “no function” alleles, classified as NUDT15 poor metabolizer at high risk of myelosuppression with standard thiopurine doses. Liver donor pharmacogenomic testing was not performed. This case highlights the consideration of pharmacogenomic testing for recipient and donor prior to thiopurine use in liver‐transplant recipients.

2 July 2026 in JAPhA Practice Innovations
Verified
Journal Article
Open access
ASApril Schultz
April Schultz
DGDavid Gregornik
David Gregornik
JNJenny Q. Nguyen
Jenny Q. Nguyen

7 November 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
CBChad Bousman
Chad Bousman
RBRebecca Brand
Rebecca Brand
KCKelsey Cook
Kelsey Cook
DGDavid B Gregornik
David B Gregornik
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
Descriptions of how pediatric‐focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult‐focused institutions. We aimed to provide a detailed description of how pediatric‐focused institutions across the world implemented pharmacogenomic testing in clinical practice. A survey was distributed to members of the Pharmacogenomics Global Research Network to assess program infrastructure, implementation efforts, genes tested, method of testing, and clinical decision support. The survey was completed by 43 institutions that have implemented pharmacogenomics: 12 pediatric‐focused, 10 adult‐focused, and 21 institutions serving all ages. All pediatric‐focused institutions provide testing for CYP2C19 , CYP2C9 , CYP2D6 , CYP3A5 , NUDT15 , and TPMT . Psychiatry and hematology/oncology were the specialties most commonly reported as implementing pharmacogenomics at pediatric‐focused institutions. Most institutions have clinical decision support incorporated into their electronic health record and a similar number of compensated employees contributing to the program, regardless of age group focus. All pediatric‐focused institutions were non‐profit and often received programmatic funding from internal sources. A higher proportion of pediatric‐focused sites provided patient education (92%) compared to adult‐focused (60%) and those caring for all ages (76%). Pediatric‐focused institutions interested in implementing or expanding their pharmacogenomic services will encounter many of the same opportunities and considerations as adult institutions. The results of this survey highlight additional unique considerations for pediatric‐focused pharmacogenomic implementation and may serve as a roadmap for pediatric institutions interested in implementing or expanding pharmacogenomic services.